Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024

Executive Summary

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
• Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Description
Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:
• The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
• The impact of higher inflation in many countries and the resulting spike in interest rates.
• The continued but declining impact of COVID-19 on supply chains and consumption patterns.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Type: Solid; Liquid
2) By Product: Vitamin E and Pioglitazone; Ocaliva; Elafibranor; Selonsertib and Cenicriviroc; Other Products
3) By Disease Cause: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
4) By Sales Channel: Hospital Pharmacy; Retail Pharmacy; Online Provider
5) By Application: Oral; Parenteral

Key Companies Mentioned: NGM Biopharmaceuticals Inc.; Novartis AG; AstraZeneca plc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned

• NGM Biopharmaceuticals Inc.
• Novartis AG
• AstraZeneca plc.
• GlaxoSmithKline plc.
• F. Hoffmann-La Roche AG
• The Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Genfit SA
• Cadila Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Blade Therapeutics Inc.
• Cempra Pharmaceuticals Inc.
• Galmed Pharmaceuticals Inc.
• Immuron Limited
• Terns Pharmaceuticals Inc.
• Tobira Therapeutics Inc.
• Arena Pharmaceuticals Inc.
• Vivus LLC
• Arisaph Pharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Raptor Pharmaceutical Inc.
• VERVA Technologies Pvt. Ltd.
• Viking Therapeutics
• Conatus Pharmaceuticals Inc.
• One Way Liver S.L.
• BioPredictive S.A.S.
• Madrigal Pharmaceuticals Inc.
• Cirius Therapeutics
• Akero Therapeutics Inc.
• Echosens